Lv1
50 积分 2022-07-22 加入
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
12小时前
已完结
A High-Potency Protein That Normalizes Body Weight in DIO Mice through Triple Agonism at FGF21, GLP1, and GIP Receptors
3个月前
已完结
Precision Oncology: 2025 in Review
6个月前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
7个月前
已完结
Mapping the effectiveness and risks of GLP-1 receptor agonists
7个月前
已完结
The non-small-cell lung cancer drug market
7个月前
已完结
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2
9个月前
已完结
Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer
11个月前
已完结
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer
11个月前
已完结
First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
11个月前
已完结
皖公网安备34019202002308
